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Tumour necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL/APO2L) is a recently identified member of the TNF family,
which induces programmed cell death in a variety of neoplastic cell types, but not in most nonneoplastic cells. In this study, we report
on the identification of two novel alternative splice variants of TRAIL in neoplastic and non-neoplastic human cells lacking either exon
3 (TRAIL-b) or exons 2 and 3 (TRAIL-g). In both splice variants, loss of exon 3 resulted in a frame shift generating a stop codon with
consecutive extensive truncation in the extracellular domain. Ectopic expression revealed a loss of proapoptotic potential for both
alternative splice variants. In contrast to the predominantly cytoplasmatic localisation of GFP-tagged TRAIL-a and TRAIL-b, TRAIL-g
showed an additional association with the cell surface and nuclear membrane. In conclusion, alternative splicing might be involved in
fine tuning of TRAIL-induced apoptosis and underlines the complexity of the TRAIL system.
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TRAIL/APO2L (tumour necrosis factor related apoptosis-inducing
ligand or TRAIL-a) is a recently identified type II transmembrane
protein that belongs to the TNF family (Wiley et al, 1995; Pitti et al,
1996) and is processed proteolytically at the cell surface to form a
soluble ligand (Mariani and Krammer, 1998). In contrast to other
members of the TNF family, such as CD95L/FasL and TNF, TRAIL
has been detected in a wide variety of both non-neoplastic and
neoplastic cell types and tissues (Wiley et al, 1995; Pitti et al, 1996)
and was found to induce programmed cell death in cancer cells,
but not in most normal cells (Gura, 1997; Sheridan et al, 1997;
Walczak et al, 1997; Ashkenazi et al, 1999; Dejosez et al, 2000).
Consistently, TRAIL was shown to suppress growth of human
tumours transplanted into mice (Walczak et al, 1999) and to
improve survival of the tumour-bearing animals (Ashkenazi et al,
1999). Although repeated intravenous injections of TRAIL in
primates did not cause detectable toxicity to non-neoplastic tissues
(Ashkenazi et al, 1999), in vitro susceptibility to TRAIL-mediated
apoptosis was reported recently for human hepatocytes (Jo et al,
2000).
Induction of apoptosis by TRAIL seems to be more complex
than apoptosis mediated by other members of the TNF family,
because four different TRAIL-binding receptors have been
identified so far (Griffith and Lynch, 1998; Degli-Esposti, 1999).
TRAIL-R1/DR4 and TRAIL-R2/DR5/KILLER/TRICK2 exhibit a
death domain in their cytoplasmatic regions and signal apoptotic
cell death upon overexpression (Gura, 1997; Pan et al, 1997a,b;
Sheridan et al, 1997). In contrast, ectopic overexpression of
TRAIL-R3/DcR1/TRID, which lacks a cytoplasmatic region (Degli-
Esposti et al, 1997b; MacFarlane et al, 1997; Pan et al, 1997a;
Sheridan et al, 1997; Mongkolsapaya et al, 1998), and TRAIL-R4/
DcR2/TRUNDD, which exhibits only a truncated intracellular
death domain (Degli-Esposti et al, 1997a; Marsters et al, 1997;
Kischkel et al, 2000), rather protects cells from TRAIL-induced
apoptosis (Degli-Esposti et al, 1997a; Pan et al, 1997a; Kischkel
et al, 2000). Although the molecular pathways of TRAIL-induced
programmed cell death are still under investigation, recent studies
have demonstrated the recruitment of FADD and DAP3 as
adaptors in the death-inducing signalling complex (DISC) and
activation of caspase-8 (Bodmer et al, 2000a; Kischkel et al, 2000;
Kuang et al, 2000; Sprick et al, 2000; Miyazaki and Reed, 2001).
Several studies found a correlation between TRAIL resistance
and expression levels of TRAIL in human cancer cell lines
and keratinocytes (Rieger et al, 1999; Zhang et al, 1999; Dejosez
et al, 2000). Moreover, the presence of intracellular caspase-8
(Eggert et al, 2001) and antiapoptotic proteins such as c-FLIP
(Griffith et al, 1998; Leverkus et al, 2000) and/or activation of the
transcription factor NF-kB seem to determine TRAIL sensitivity
(Jeremias et al, 1998; Goke et al, 2000; Keane et al, 2000; Bernard
et al, 2001; Franco et al, 2001; Oya et al, 2001; Wuchter et al, 2001).
Transcriptional modification by alternative splicing is known to
be involved in the regulation of apoptotic cell death in mammalian
cells as well (Jiang and Wu, 1999). Thus, several apoptosis-related
genes have been identified, for example, murine CD95L (Ayroldi
et al, 1999), CD95 (Cascino et al, 1995), caspase-2, -8, -9 (Jiang et al,
1998; Srinivasula et al, 1999; Cote et al, 2001; Eckhart et al, 2001),
cFLIP (Scaffidi et al, 1999) and survivin (Mahotka et al, 1999;
Conway et al, 2000; Krieg et al, 2002), which are alternatively Revised 4 November 2002; accepted 25 November 2003
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sprocessed and thereby may exert distinct regulatory functions in
the fine tuning of apoptosis.
In this report, we describe the identification of two novel TRAIL
splice variants, i.e., TRAIL-b and TRAIL-g, in non-neoplastic and
neoplastic cells. The lack of exon 3 in TRAIL-b and of exons 2 and
3 in TRAIL-g results in massive truncation of the extracellular
binding domain and loss of proapoptotic potential.
MATERIALS AND METHODS
Cell lines and cultures
All RCC cell lines (n¼30) used in this study were derived from
typical representatives of the clear cell, chromophilic/papillary and
chromophobe types of RCC, established in our laboratory as
previously described (Gerharz et al, 1999). The cell lines were
maintained with Dulbecco’s modified Eagle’s medium (DMEM,
Gibco, Karlsruhe, Germany) supplemented with 10% fetal calf
serum, penicillin and streptomycin. PBMCs were cultivated in
RPMI medium (Gibco, Karlsruhe, Germany) supplemented with
10% fetal calf serum, penicillin and streptomycin. All cell lines and
PBMCs were cultured at 371C in an atmosphere with 5% CO2.
Stimulation of PBMCs
Buffy coats of blood samples from four healthy independent
donors were collected according to standard procedures. For
stimulation, cells were seeded at a density of 5 10
5 cellsml
 1 and
treated with 10mgml
 1 concanavalin A (Sigma-Aldrich, Deisen-
hofen, Germany). Stimulated PBMCs were collected for RNA
extraction after emergence of cell blasts (2–4 days).
RNA extraction
Total RNA was isolated from the cultured RCC cell lines, PBMCs,
mouse tissues and the mouse tumour cell line RAW 264.7 using the
RNeasy kit (Qiagen, Hilden, Germany). The integrity of RNA (28S/
18S ribosomal RNA) was controlled by electrophoresis followed by
staining with ethidium bromide.
Reverse transcription (RT) and PCR amplification of
TRAIL
For cDNA synthesis, 2mg of total RNA was reversely transcribed in
a final volume of 30ml containing 25mM of each dNTP (Stratagene,
Heidelberg, Germany), 100pmol random hexamer primer (Strata-
gene), 20U of recombinant RNasin RNase inhibitor (Promega,
Heidelberg, Germany) as well as 5U of AMV reverse transcriptase
(Promega) with the corresponding RT buffer. The RT reactions
were incubated at 551C for 1h.
PCR amplification of human TRAIL and GAPDH was performed
in a final volume of 50ml containing 3ml first-strand cDNA
solution, 2.5U of Taq polymerase, 1 PCR buffer, 25mM of each
dNTP (Qiagen, Hilden, Germany) and 25pmol of each 30 and 50
TRAIL-specific oligonucleotide (forward primer, 50-GAA TCC CAT
GGC TAT GAT GGA GGT CCA G-30 and reverse primer, 50-GGA
TTC GAG GAC CTC TTT CTC TCA CTA-30) (GenBank accession
number U37518) or 30 and 50 GAPDH-specific oligonucleotide
(forward primer, 50-ACG GAT TTG GTC GTA TTG GGC G-30 and
reverse primer, 50-CTC CTG GAA GAT GGT GAT GG-30)
(GenBank accession number J04038). Conditions of PCR were as
follows: initial denaturation step at 941C for 2min, followed by 35
cycles (TRAIL) or 27 cycles (GAPDH) of denaturation for 30s,
annealing for 1min at 581C (TRAIL) or 641C (GAPDH), extension
at 721C for 1min and a final extension step at 721C for 5min. PCR
products were electrophoresed on 3% agarose gels containing
ethidium bromide and visualised under UV transillumination.
Real-time PCR of murine TRAIL was performed on the
LightCycler
s (Roche Diagnostics, Mannheim, Germany). Ampli-
fication was performed in a total volume of 20ml in the presence of
2ml1 0 SYBR Green Fast Start Reaction Mix (Roche Diagnostics),
3m M MgCl2, 25pmol of each 30 and 50 TRAIL-specific oligonucleo-
tide (forward primer, 50-GAA TCC CTG CAT TGG GAA GTC AGA-
30 and reverse primer, 50-GGA TCC TTA ATT AAA AAG GCT CCA
AAG AAG-30) (GenBank accession number U37522) and 2mlo f
cDNA (or water as negative control). Real-time PCR was carried
out in glass capillaries with an initial denaturation step of 10min at
951C, followed by 65 cycles of 0s at 951C, 4s annealing at 721C, and
elongation for 36s at 721C. Melting curve was directly performed
after amplification with an initial denaturation of 0s at 951C, a
temperature delay at 821C for 30s and a continous heating on 951C
for 0s with a slope of 0.11Cs
 1. To confirm the results, PCR
products were electrophoresed on 3% agarose gels containing
ethidium bromide and visualised under UV transillumination.
Sequence analysis
Bands of interest were excised from agarose gels and isolated using
the QIAquick gel extraction kit (Qiagen), ligated into the pGEM-T-
cloning vector (Promega) and cloned in accordance to standard
protocols. Plasmid DNA was recovered employing the Plasmid
Mini Kit (Qiagen), cycle sequenced using T7 or SP6 site-specific
primers, and analysed with an ABI Prism 310 sequencing
apparatus (Applied Biosystems, Weiterstadt, Germany).
Cloning of TRAIL coding sequences
To generate GFP-tagged constructs of TRAIL variants, the coding
cDNA sequences of the three TRAIL variants were amplified by
PCR as described above. PCR amplification products were cloned
into the pGEM-T-vector as described above, digested with EcoRI
and BamHI, ligated into the mammalian expression vector pEGFP-
C1 (Clontech, Heidelberg, Germany) and cloned according to
standard protocols. GFP-TRAIL-a construct was cloned as recently
described (Kagawa et al, 2001).
Transfection of cultured cells, assessment of cell viability
and apoptosis as well as analysis of subcellular localisation
by confocal laser scanning microscopy
Subconfluent TRAIL-sensitive HeLa cells were transiently trans-
fected in 24-wells using polyfect transfection reagent, as described
by the manufacturer (Qiagen). HeLa cells were incubated with the
DNA and the transfection reagent for 24h. To determine the
number of cells that underwent apoptosis, HeLa cells were seeded
on coverslips in 24-well plates, cultivated for 24h and transfected
as described above. After transfection, cells were washed twice with
sterile PBS and fixed for 10min in ice-cold methanol. Cells were
treated with DAPI staining solution (0.1mgml
 1) for 5min and
washed twice with PBS. Up to 300 cells were counted in five
different fields per preparation using an Axioscop fluorescence
microscope (Zeiss, Germany). The percentage of apoptotic cells
was calculated as the ratio between the number of GFP-positive
cells with fragmented nuclei and all GFP-positive cells. The data
presented are the mean 7s.d. from three replicates.
Cell number was analysed using the colorimetric MTT assay as
described before (Mosman, 1983) and measured on a spectro-
photometric Titertek Multiskan plate reader (Labsystems, Finland)
at 570nm. The percentage of viable cells in each well was
calculated as the ratio between the absorbance of TRAIL-a-,
TRAIL-b- or TRAIL-g-transfected cells and the absorbance of
vector control-transfected cells. The data presented are the mean
7s.d. from six replicates.
Statistical significance was considered for P-values of Student’s
t-test less than 0.05. Transfection efficiency was directly
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transfection efficiencies varied between 20 and 30% for HeLa cells.
To analyse the subcellular localisation of TRAIL-variants,
HEK293 cells in the exponential growth phase were seeded onto
sterile coverslips in six-well plates at a density of 1 10
5 cells
well
 1. After 24h, cells were transfected as described above.
Afterwards, cells were washed two times in PBS, fixed in
ice-cold methanol for 10min and incubated with endoplasmatic
reticulum-specific fluorescence dye concanavalin A Alexa-564
(Molecular Probes, Eugene, USA) (25mgml
 1) for 30min. Cover-
slips were washed again in PBS, mounted and examined using a
confocal laser scanning system TCS-NT (Leica, Bensheim,
Germany).
Western blot analysis
Protein extracts from transiently transfected HeLa cells were
isolated by disrupting cells in lysis buffer (100mM NaCl, 10mM
Tris-HCl pH 7.6, 1mM EDTA pH8 and protease inhibitor). Protein
samples (up to 50mg) were electrophoresed in 12% SDS–
polyacrylamide gels at 70mA for 4h. Blotting to Opitran BA-S85
nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany)
was performed for up to 2h at 650mA in a tank of transfer buffer
pH 8.3 (25mM Tris-HCl, 1925mM glycine, 20% methanol) using
the Hoefer TE series Transphor electrophoresis unit (Hoefer
Scientific Intsruments, San Fransisco, USA). To verify transfer
efficiency and protein integrity, nitrocellulose membranes were
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Figure 1 Expression of different TRAIL mRNA variants in neoplastic and non-neoplastic human cells. (A) TRAIL-a is the dominant transcript in renal cell
carcinoma cell lines, whereas TRAIL-b and -g show low expression levels only. Of note, expression of TRAIL-g was not observed in chromophilic/papillary
(chromphi-1 to -4) and chromophobe (chrompho-A) RCCs. (B) The alternative splice variants TRAIL-b and TRAIL-g are expressed at low levels in both
unstimulated ( ) and concanavalin A-stimulated (+) PBMCs. (C) No alternative TRAIL splice variants could be detected in mouse liver and kidney or in the
mouse tumour cell line RAW 264.7. Melting curve analysis showed a distinct peak for full-length TRAIL in liver and kidney tissue, but no additional signals for
splice variants.
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sstained with Ponceau S 0.2%. Afterwards, membranes were
blocked in blocking buffer (100mM Tris-HCl, pH 7.5, 150mM
NaCl, 0.2% Tween 20) plus 3% nonfat dry milk and 1% BSA for 2h
at room temperature. Immunodetection of GFP-TRAIL-fusion
proteins was carried out by incubating membranes with a 1:2000
dilution of monoclonal mouse anti-GFP antibody JL-8 (Clontech,
Palo Alto, USA) overnight at 41C. PARP cleavage was detected by
incubating membranes with a 1:500 dilution of monoclonal mouse
anti- human PARP antibody, clone AC10.5 (Pharmingen, San
Diego, USA) overnight at 41C. Subsequently, membranes were
incubated with a 1:1000 dilution with horseradish-peroxidase
linked anti-mouse antibody (Amersham Pharmacia, Freiburg,
Germany) for 1.5h.
Proteins were detected by incubation with Lumi-Light substrate
(Roche, Mannheim, Germany). Equal loading was confirmed by b-
actin detection with a mouse anti-b-actin-specific antibody, clone
AC-15 (Sigma-Aldrich, Taufeirchren, Germany). Data on X-ray
films were quantified by densitometry with the program Tina 20
(raytest Isotopenmessgera ¨te GmbH, Germany).
RESULTS
Identification of two novel TRAIL splice variants
As revealed by RT–PCR analysis, all RCC cell lines (n¼30)
expressed TRAIL-a, irrespective of their histological types
(Figure 1A). Besides the expected amplification product of
371bp, however, two additional bands of 328 and 190bp were
coamplified. These three amplification products were sequenced.
The largest band was identified as regularly spliced TRAIL-a,
whereas the 328bp product was identified as a TRAIL variant with
a deletion of 43 nucleotides corresponding to nucleotides 358–400
of the TRAIL-a cDNA of the human TRAIL sequence (GenBank
Accession no. U37518). The smallest PCR product (190bp) lacked
nucleotides 220–357.
Although the genomic organisation and the exon–intron
boundaries of TRAIL had recently been published (Gong and
Almasan, 2000), we repeated the database analysis by running
advanced BLAST, looking for a genomic clone that contains parts
of the human TRAIL gene. This database search revealed that the
Homo sapiens Chromosome 3-clone hRPK.44 A (Accession no.
AC007051) contained the entire coding sequence of TRAIL.
Subsequently, we determined the exon–intron organisation of
the human TRAIL gene, which consists of five exons (Figure 2). Of
note, we observed a difference in two nucleotides (position 143697
and 145990) marked by squares in Figure 2 when compared to the
published sequence (Gong and Almasan, 2000). According to the
genomic organisation, the 43 nucleotides deleted in the 328bp long
amplification product corresponded to exon 3 and, therefore, we
designated this new alternative splice variant as TRAIL-b. The
smaller band (190bp) was found to lack both exon 2 (138
nucleotides) and exon 3 and, therefore, was designated as TRAIL-g.
Additional amplification of genomic DNA by PCR showed no
product and excluded the presence of pseudogenes.
To investigate whether the novel TRAIL splice variants are
exclusively generated in neoplastic cells, we performed RT–PCR
with unstimulated and stimulated PBMCs showing that the
alternative splice variants TRAIL-b and TRAIL-g are expressed
in non-neoplastic cells as well (Figure 1B). No alternative TRAIL
splice variants, however, could be detected in mouse liver and
kidney or in the mouse tumour cell line RAW 264.7 (Figure 1C).
This observation strongly suggests that alternative splicing of
TRAIL may be a species-restricted phenomenon.
ex1
ex2
ex3
ex4
ex5
Figure 2 Genomic organisation of the human TRAIL gene. The cDNA sequence of human TRAIL (accession no. U37518) is marked in bold letters within
the Homo sapiens chromosome 3, clone hRPK.44 A 1 (accession no. AC007051). SD and SA sites at the exon–intron boundaries are underlined. Of note,
differences between our analysis of the genomic organisation and a recent publication (Gong and Almasan, 2000) are marked by squares. The stop codon
generated by alternative splicing of exons 2 and 3 is marked by a black-shaded square.
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exon–intron boundaries of exons 2 and 3 are suitable for
alternative splicing
Computational analysis with the Signal program (PC/GENE
package) showed that exon 2 as well as exon 3 are flanked by
splice donor (SD) and splice acceptor (SA) sites matching to the
consensus sequence of common SD sites ({C/A}AG|GT{A/G}AGT)
and SA sites ({T/C}11N{C/T}AG|G) as shown in Figure 3A. Both the
SA sites at position 140298–140457 of exon 2 and at position
143641–143700 of exon 3 contain the AG bases of SA sites as well
as the GT bases of the SD sites that are necessary for post-
transcriptional splicing on intron–exon boundaries. The necessary
GT bases of SD sites for splicing processes exist also at the exon–
intron boundaries of exons 2 and 3. Taken together, these data
indicate that post-transcriptional processing of the TRAIL-pre-
mRNA leads to the generation of three alternative splice products,
i.e., TRAIL-a, TRAIL-b and TRAIL-g (Figure 3B).
Alterations of protein domains in the novel TRAIL
isoforms and functional implications
Computational analysis of TRAIL-a and its novel alternative splice
variants showed that loss of exon 3 resulted in a frame shift
generating a stop codon with consecutive truncation in the
extracellular domains of both TRAIL-b and -g. This truncation
resulted in a 98 amino-acids long TRAIL-b and a 52 amino-acids
long TRAIL-g (Figure 4A). Moreover, PSORT II analysis (Nakai
and Horton, 1999) identified KIFL, a KKXX-like motif known as
endoplasmatic reticulum membrane retention signal at the C-
terminus of both TRAIL-b and -g. PROSITE scan (Bairoch, 1991)
also identified potential protein kinase C phosphorylation sites
between amino acids 92–94 of TRAIL-b and amino acids 46–48 of
TRAIL-g, immediately adjacent to the potential endoplasmatic
membrane retention signal. TRAIL-b also contains a potential
cAMP- and cGMP-dependent protein kinase phosphorylation site
between amino acids 89- and 92 (Figure 4B).
A
B
exon 1
exon 1
exon 1
exon 1 exon 4 exon 5
exon 4 exon 5
exon 4
exon 4
exon 5
exon 5 exon 2 exon 3
exon 2
exon 2
exon 3
132 nt 138 nt 43 nt 428 nt 105 nt
pre-mRNA
TRAIL-  mRNA
TRAIL-  mRNA
TRAIL-  mRNA
Figure 3 SD and SA sites flanking exons 2 and 3 (A) and the resulting TRAIL mRNAs (B).
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membrane retention signal at the C-terminus of both TRAIL-b and
-g, PSORT II analysis predicted a preferential cytoplasmatic
localisation for all TRAIL isoforms (data not shown). To further
investigate the subcellular localisation of TRAIL-a and its
alternative splice variants, GFP-fused TRAIL variants were
ectopically overexpressed in HEK293 cells. Using concanavalin A
Alexa-594 as a marker of endoplasmatic reticulum, confocal laser
microscopy did not reveal a selective accumulation of TRAIL-b or
TRAIL-g in the endoplasmatic reticulum (Figure 5). However,
TRAIL-g was found to produce a more intensive fluorescence of
the cell surface and nuclear membrane when compared to the
other splice variants.
Using HeLa cells known to be sensitive to TRAIL-mediated
apoptosis (Harper et al, 2001), ectopic expression of TRAIL
variants revealed marked differences in the apoptotic activity of
TRAIL-a and its novel alternative splice variants: ectopic expres-
sion of TRAIL-a led to huge clusters of apoptotic cells, which were
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Figure 4 Structural alterations of protein domains in the novel TRAIL isoforms. (A) Multiple alignment of the three TRAIL isoforms was performed by
Clustal W (Thompson et al, 1994) and enhanced with Boxshade. Dark shading: residues are highly conserved; light shading: residues are less well conserved;
not shaded: residues are not conserved. (B) Protein sequences were analysed by PROSITE scan. Potential domains and modification sites are marked. A
frame shift because of alternative splicing results in a potential endoplasmatic reticulum membrane retention (ER) signal at the C-terminus adjacent to new
potential PKC-phoshorylation sites in both TRAIL-b and -g. Light grey box ¼ newly generated ER-signal containing domain. ICD ¼ intracellular domain;
ECD ¼ extracellular domain; TM ¼ transmembrane region; ER ¼ endoplasmatic reticulum membrane retention signal; cAMP ¼ cAMP-dependent
protein kinase phoshorylation site; CK2 ¼ casein kinase II phosphorylation site; TYR ¼ tyrosine kinase phosphorylation site; PKC ¼ protein kinase C
phosphorylation site.
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snot observed after transfection with the other TRAIL variants or
the vector control (Figure 5B). DAPI staining permitted the
identification of fragmented or condensed nuclei indicative for
apoptosis (Figure 5C) and permitted a visual quantification of
apoptosis (see Material and Methods). Using this assay, a
significant decrease of apoptotic cells was observed after ectopic
expression of GFP-TRAIL-b or GFP-TRAIL-g or the vector control
when compared to GFP-TRAIL-a-transfected HeLa cells
(Figure 5D). The decrease of apoptotic potential observed for
GFP-TRAIL-b and GFP-TRAIL-g was paralleled by a significant
increase of cell viability as demonstrated by MTT assays
(Figure 5E). To further confirm the effects of the different TRAIL
variants on apoptosis, PARP cleavage was analysed by a
monoclonal mouse antibody, that recognises a 85kDa cleavage
product besides the 116kDa uncleaved PARP. PARP cleavage was
found to be enhanced three-fold by ectopic expression of TRAIL-a
in comparison with the other TRAIL variants or the vector control
(Figure 5F).
To ensure that the observed effects were based on protein
expression of all TRAIL variants, the expression of the fusion
TRAIL-  TRAIL-  TRAIL-  Vector control
Concanavalin A
     Alexa-594
Merge
TRAIL variants
(+ vector control)
A
BC
GFP/DAPI DAPI
GFP-TRAIL- 
GFP-TRAIL- 
GFP-TRAIL- 
Vector control
P = 0.033
P = 0.0356
P = 0.855
P = 0.030
P = 0.045 90
80
70
60
50
40
30
20
10
0
P
e
r
c
e
n
t
a
g
e
 
o
f
 
a
p
o
p
t
o
t
i
c
 
c
e
l
l
s
 
±
 
s
.
d
.
GFP-TRAIL- 
GFP-TRAIL- 
GFP-TRAIL- 
Vector control
D
P = 0.216
Figure 5 A–D Differential subcellular localisation and lost proapoptotic potential of the novel TRAIL variants. (A) Confocal laser scanning microscopy
revealed a prominent cytoplasmatic localisation of all GFP-tagged TRAIL variants. The endoplasmatic reticulum was marked with the endoplasmatic
reticulum-specific fluorescence dye concanavalin A Alexa-594. Yellow staining in ‘merge’ indicates colocalisation of all GFP-tagged TRAIL variants and the
endoplasmatic reticulum. Of note, GFP-tagged TRAIL-g additionally showed a prominent fluorescence of both the cell surface and the nuclear membrane,
which was not observed for the other TRAIL variants. HeLa cells known to be sensitive to TRAIL-mediated apoptosis (Harper et al, 2001) were transfected
with GFP constructs containing the different TRAIL isoforms or the empty vector. (B) Phase contrast microscopy of the transfected cells showed prominent
clusters of apoptotic cells (arrows) in cultures of GFP- TRAIL-a transfected cells but not after transfection of other TRAIL variants or the vector control. (C)
DAPI staining of nuclei permitted an identification of nuclei with fragmented or condensed chromatin, indicative for apoptotic cells (arrows), which could
easily be distinguished from cells with intact nuclei under UV light. (D) Visual quantification of apoptosis was done by counting all GFP-positive cells as well as
all GFP-positive cells with fragmented/condensed nuclei. The percentage of apoptotic cells was calculated as the ratio between the number of GFP-positive
cells with fragmented or condensed nuclei and all GFP-positive cells. (Continued on next page.)
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sproteins was confirmed by Western blot analysis using a
mononoclonal mouse anti-GFP anbtibody (Figure 5G).
DISCUSSION
In this study, we report on the identification of two novel splice
variants of TRAIL, i.e., TRAIL-b and TRAIL-g, in RCC cell lines of
all major histological subtypes. These previously unknown splice
variants were not clearly detectable in RNase protection assays
(Dejosez et al, 2000), because only 43bp (TRAIL-b) or 181bp
(TRAIL-g) differences in length were found in comparison with the
primarily identified TRAIL-a transcript (Wiley et al, 1995; Pitti
et al, 1996). It was especially intriguing to detect these splice
variants in non-neoplastic human cells as well, whereas no
corresponding splice variants were found in different cell types
of murine origin.
Alternative splicing permits a high degree of protein diversity
generating structurally and functionally distinct proteins that
differ in their subcellular localisation, molecular targets or
stability. Splice variants have previously been found to play a
key role in the regulation of apoptosis as well, determining the
actions of many apoptosis-related genes at all levels of apoptotic
signalling pathways (Jiang and Wu, 1999). Thus, the CD95 (APO-1,
Fas) receptor exists in membrane-bound and soluble isoforms
which antagonistically affect apoptosis (Jiang and Wu, 1999). The
Bcl-2 family encompasses genes, for example, Bcl-X and its
different splice variants Bcl-XL/XS, which antagonistically deter-
mine the susceptibility to cell death signals (Boise et al, 1993).
Finally, different isoforms of caspases (Srinivasula et al, 1999; Cote
et al, 2001; Eckhart et al, 2001) and inhibitor of apoptosis (IAP)
proteins (Mahotka et al, 1999; Conway et al, 2000) are generated by
alternative splicing. The novel TRAIL isoforms described in this
study show an extensive loss of their extracellular binding domain,
which plays a key role for trimeric stability, ligand–receptor
binding capacity and apoptotic signalling (Pitti et al, 1996;
Sheridan et al, 1997; Griffith and Lynch, 1998; Ashkenazi et al,
1999; Bodmer et al, 2000b; Kagawa et al, 2001). Consequently, the
novel truncated TRAIL isoforms should be unable to form stabile
dimeric or trimeric receptor–ligand complexes and fail to trigger
TRAIL mediated-apoptosis as demonstrated by our transfection
experiments.
At first sight, therefore, TRAIL-b and TRAIL-g may interfere
with the fine tuning of TRAIL actions simply by reducing the
amount of full-length ligand. In fact, the generation of truncated
isoforms has been suggested as an additional mechanism to
quantitatively regulate gene expression and action, because the
mRNAs of all isoforms originate from the same pre-mRNA
precursor pool (Jiang and Wu, 1999). Interestingly in this context,
however, ectopically overexpressed TRAIL-g exhibited a more
prominent association with the cell surface and the nuclear
membrane when compared to both TRAIL-a and TRAIL-b. Further
experimental work, therefore, will have to show whether these
alternative splice variants actually play a passive regulatory role for
TRAIL-mediated apoptosis only or acquired novel functional
properties as well. In any case, the identification of two novel splice
variants may have implications for our understanding of TRAIL-
mediated apoptosis in neoplastic and non-neoplastic human cells.
ACKNOWLEDGEMENTS
We thank Sigrid Khalil, Michael Ringler and Martina Bellack for
technical assistance. The results of this work are part of the PhD
thesis of Thomas Krieg and the MD thesis of Andreas Krieg. This
work was supported by a grant from the Deutsche Forschungs-
gemeinschaft and by the Stiftung fu ¨r Altersforschung.
GFP-TRAIL- 
GFP-TRAIL- 
GFP-TRAIL- 
TRAIL (50 ng ml -1 ; 12 h)
Vector control
GFP-TRAIL- 
GFP-TRAIL- 
GFP-TRAIL- 
vector control
Untransfected
Untreated control
F
PARP p116
PARP p85
3.5
2.5
1.5
2
3
1
0.5
0
R
a
t
i
o
 
c
l
e
a
v
e
d
 
P
A
R
P
/
P
A
R
P
 
(
 
S
D
)
58 kDa (GFP-TRAIL- )
38 kDa (GFP-TRAIL- )
32 kDa (GFP-TRAIL- )
27 kDa (GFP)
42 kDa ( -actin)
P = 0.011
P = 0.499
P = 0.049
140
120
100
80
60
40
20
0
V
i
a
b
i
l
i
t
y
 
(
p
e
r
c
e
n
t
 
o
f
 
t
h
e
 
v
e
c
t
o
r
 
c
o
n
t
r
o
l
)
 
±
 
s
.
d
.
 
±
 
GFP-TRAIL- 
GFP-TRAIL- 
GFP-TRAIL- 
E G
Figure 5 ContinuedE–G This visual apoptosis assay (n¼3) further confimed the loss of proapoptotic potential for GFP-TRAIL-b and GFP-TRAIL-g,
which also became evident (E) from an increase of surviving cells in our MTT assays (n¼6). (F) Immunodetection of the caspase-3-dependent ‘death
substrate’ PARP showed enhancend cleavage only after ectopic expression of GFP-TRAIL-a. To ensure the detection of this cleavage product, protein
lysates from TRAIL-treated control cells were separated on the same gel. The data presented are the mean 7s.d. from three independent transfections. (G)
To show that the recombinant TRAIL variants are expressed on protein level, whole protein lysates of transfected HeLa cells were separated by SDS gels
and immunodetection of GFP fusion proteins with anti-GFP-IgG was carried out after blotting on nitrocellulose membrane.
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